ClinicalTrials.Veeva

Menu
R

Retina Vitreous Associates of Florida | St. Petersburg

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
JNJ-81201887
Elamipretide
AG-73305
GT005
Zimura
BI 764524
BI 771716
RO7200220
Vamikibart

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 13 total trials

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling
Macular Degeneration
Geographic Atrophy
Other: Sham Procedure
Drug: JNJ-81201887
Recently updated

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Enrolling
Neovascular Age-related Macular Degeneration
Drug: LUCENTIS (Ranibizumab Injection)
Device: PDS Implant With Ranibizumab 100 mg/ml

This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 w...

Enrolling
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Ranibizumab refill exchange

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure
Locations recently updated

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with g...

Enrolling
Geographic Atrophy
Biological: OpRegen

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join...

Enrolling
Diabetic Retinopathy
Drug: BI 764524
Drug: Aflibercept (Eylea®) - US only

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Active, not recruiting
Macular Degeneration, Age-related
Geographic Atrophy
Drug: Pegcetacoplan
Drug: Sham comparator to BI 771716
Status recently updated

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular deg...

Enrolling
Active, not recruiting
Age Related Macular Degeneration (ARMD)
Drug: Elamipretide
Drug: Placebo

Trial sponsors

Boehringer Ingelheim logo
Genentech logo
Janssen (J&J Innovative Medicine) logo
Roche logo
A
G
I
Stealth BioTherapeutics logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems